Zai Lab EPS - Earnings per Share 2016-2022 | ZLAB
Zai Lab eps - earnings per share from 2016 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Zai Lab Annual EPS |
| 2021 |
$-7.58 |
| 2020 |
$-3.46 |
| 2019 |
$-3.03 |
| 2018 |
$-2.64 |
| 2017 |
$-2.32 |
| 2016 |
$-3.97 |
| 2015 |
$-2.07 |
| Zai Lab Quarterly EPS |
| 2022-03-31 |
$-0.86 |
| 2021-12-31 |
$-2.17 |
| 2021-09-30 |
$-1.01 |
| 2021-06-30 |
$-1.76 |
| 2021-03-31 |
$-2.64 |
| 2020-12-31 |
$-0.88 |
| 2020-09-30 |
$-0.84 |
| 2020-06-30 |
$0.00 |
| 2020-03-31 |
$-0.66 |
| 2019-12-31 |
$0.00 |
| 2019-09-30 |
$0.00 |
| 2019-06-30 |
$0.00 |
| 2018-12-31 |
$0.00 |
| 2017-12-31 |
$0.00 |
| 2017-06-30 |
$0.00 |
| 2016-12-31 |
$0.00 |
| 2015-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$3.497B |
$0.144B |
|
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
|
